Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Charalabos-Markos Dintsios"'
Publikováno v:
Systematic Reviews, Vol 7, Iss 1, Pp 1-9 (2018)
Abstract Background The 20–70% participation of diabetes patients in lifestyle interventions (LSI) worldwide seems to be rather sub-optimal, in spite of all intents of such interventions to delay further progress of the disease. Positive effects th
Externí odkaz:
https://doaj.org/article/4427a1665e58434e93a74ee249958c08
Autor:
Thomas R. Staab, Miriam Walter, Sonja Mariotti Nesurini, Charalabos-Markos Dintsios, J.-Matthias Graf von der Schulenburg, Volker E. Amelung, Jörg Ruof
Publikováno v:
Health Economics Review, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Background According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from th
Externí odkaz:
https://doaj.org/article/b0233d39cbbf4519bd29290918586e0e
Autor:
Katherine Ogurtsova, Thomas L. Heise, Ute Linnenkamp, Charalabos-Markos Dintsios, Stefan K. Lhachimi, Andrea Icks
Publikováno v:
Systematic Reviews, Vol 6, Iss 1, Pp 1-10 (2017)
Abstract Background Type 2 diabetes mellitus (T2DM), a highly prevalent chronic disease, puts a large burden on individual health and health care systems. Computer simulation models, used to evaluate the clinical and economic effectiveness of various
Externí odkaz:
https://doaj.org/article/d0f8c975865c43a4896415d7150b5125
Publikováno v:
International Journal of Dentistry, Vol 2012 (2012)
The aim of this systematic review was to evaluate the functionality of fixed and removable partial dentures as test interventions in relation to variations in the opposing dentition and their prosthetic restoration. The abstracts identified in the re
Externí odkaz:
https://doaj.org/article/a3ff824a729f4be994054b01fbefd4f4
Publikováno v:
Applied Health Economics and Health Policy. 20:287-290
Autor:
Charalabos-Markos Dintsios
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 22:283-297
Objective To analyze how ophthalmic drugs fared in the early benefit assessment (EBA) after its introduction in Germany up to 2020 and to quantify its impact on their negotiated prices. Methods Relevant documents were screened and essential content o
Autor:
Jürgen Grebe, Werner Arend, Andrea Icks, Christian Ohmann, J. Windolf, Charalabos-Markos Dintsios, Andreas Vogt, E. Neuhaus, K. Frommholz, Simon Thelen, Burkhard Haastert, Silke Andrich, C. Brunoni, P. Jungbluth
Publikováno v:
Osteoporosis International
Summary Our study demonstrates a strong increase in utilization of inpatient health care and clear excess costs in older people in the first year after pelvic fracture, the latter even after adjustment for several confounders. Excess costs were parti
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 21:145-157
Objective: Due to the impact of the Federal Joint Committee’s (FJC) appraisal on following price negotiations, it is crucial to understand the underlying reasons of failure in early benefit assessment (EBA) of medicinal products in Germany. Methods
Publikováno v:
PharmacoEconomics. 38:397-411
Legislation introduced in 2011 in Germany has instituted an early benefit assessment of newly licensed pharmaceuticals with a subsequent price negotiation. For orphan drugs (ODs) a special legal framework applies, which accounts for the fact that ODs
Publikováno v:
Der Diabetologe. 15:522-533
Mit dem Gesetz zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung (AMNOG) kam es in Deutschland zu einem Paradigmenwechsel im Umgang mit Arzneimittelinnovationen. Deren Erstattungsbetrag hangt nun von einer Nutzenbewertung